Cln1R151X mice contain a nonsense mutation similar to that found in patients with neuronal ceroid lipofuscinoses (NCLs).
David A. Pearce, Sanford School of Medicine of the University of South Dakota
Genetic Background | Generation |
---|---|
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Humanized sequence) | Ppt1 | palmitoyl-protein thioesterase 1 |
Cln1R151X mice contain the amino acid mutation R151X in exon 5 of the palmitoyl-protein thioesterase 1 (Ppt1) gene. CLN1 is a ubiquitous lysosomal enzyme responsible for removing palmitoyl groups from modified cysteine residues in polypeptides that have been targeted for degradation in the lysosome. Mutations in CLN1 most commonly lead to neuronal ceroid lipofuscinoses (NCL), autosomal recessive neurodegenerative disorder characterized by the progressive onset of seizures, blindness, motor and cognitive decline and premature death. These mutations most commonly lead to infantile NCL in which the patients exhibit microcephaly, seizures, motor abnormalities, ataxia and mental retardation leading to dementia, with death usually occurring by 8 to 13 years of age. Mutations can also lead to other clinical variants of NCL, such as variant forms of late-infantile NCL, juvenile NCL, and adult NCL.
In these mice, the R151X mutation introduces a nonsense mutation analogous to a Cln1 mutation commonly found patients with NCL. CLN1 proteins harboring the R151X mutation are targeted for degradation by the nonsense-mediated decay (NMD) pathway, leading to a significant decrease in CLN1 mRNA level and concurrent decrease in CLN1 enzyme activity in patient-derived lymphoblast cell lines. Tissues from heterozygous Cln1R151X mice showed a 1.42- to 1.85-fold decrease in Cln1 expression and tissues from homozygotes showed a 5.32- to 12.99-fold decrease in Cln1 expression. Mice display significant motor deficits by 3 months of age. They also have significant accumulation of autofluorescent storage material within the cortex, thalamus and hippocampus at 5 months of age, consistent with the neuropathological hallmarks of infantile NCL disease.
A targeting construct was designed to insert a C to T point mutation in exon 5 of the palmitoyl-protein thioesterase 1 (Ppt1) gene, resulting in a non-sense mutation, R151X, commonly found in humans with neuronal ceroid lipofuscinoses (NCLs). A loxP- and frt-flanked neomycin (neo) resistance cassette was inserted downstream of exon 5. This targeting construct was electroporated into 129S6/SvEv x C57BL/6J-derived embryonic stem (ES) cells and correctly targeted ES cells were injected into blastocysts. The resulting chimeric mice were bred to B6.C-Tg(CMV-cre)1Cgn/J (Stock No. 006054) to remove the floxed neo selection cassette, and offspring were crossed to remove the cre-expressing transgene. These Cln1R151X mice were maintained on a mixed background. Upon arrival at The Jackson Laboratory, mice were bred to C57BL/6J (Stock No. 000664) for at least one generation to establish the colony.
Expressed Gene | Ppt1, palmitoyl-protein thioesterase 1, mouse, laboratory |
---|---|
Site of Expression |
Allele Name | targeted mutation 1.1, David Pearce |
---|---|
Allele Type | Targeted (Humanized sequence) |
Allele Synonym(s) | Cln1R151X |
Gene Symbol and Name | Ppt1, palmitoyl-protein thioesterase 1 |
Gene Synonym(s) | |
Expressed Gene | Ppt1, palmitoyl-protein thioesterase 1, mouse, laboratory |
Strain of Origin | 129S6/SvEvTac x C57BL/6J |
Chromosome | 4 |
Molecular Note | A targeting construct was designed to insert a C to T point mutation in exon 5 of the gene, resulting in a non-sense mutation, R151X, commonly found in humans with neuronal ceroid lipofuscinoses (NCLs). A loxP- and frt-flanked neomycin (neo) resistance cassette was inserted downstream of exon 5. Cre-mediated recombination removed the floxed neomycin cassette. |
When maintaining a live colony, homozygous mice may be bred together.
When using the STOCK Ppt1tm1.1Dprc/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #026197 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Heterozygous for Ppt1<tm1.1Dprc> |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.